Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs.
Syncona, a London-based investor in healthcare companies, noted that Autolus reported a pretax loss of $52.7 million for the first quarter of 2024, widening from $39.8 million a year prior.
Notably, license revenue surged to $10.1 million from $1.3 million. However, general and administrative costs nearly doubled to $18.2 million from $9.3 million, while operating expenses classified as ‘other’ increased to $13.9 million from $677,000.
Autolus expects initial clinical data from a phase 1 dose confirmation study in refractory systemic lupus erythematosus patients in late 2024.
Syncona holds a stake of around 14% in Autolus.
Syncona shares fell 2.9% to 107.00 pence each on Friday afternoon in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.